RT Journal Article
SR Electronic
T1 ReScan, a Multiplex Diagnostic Pipeline, Pans Human Sera for SARS-CoV-2 Antigens
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.11.20092528
DO 10.1101/2020.05.11.20092528
A1 Colin R. Zamecnik
A1 Jayant V. Rajan
A1 Kevin A. Yamauchi
A1 Sabrina A. Mann
A1 Gavin M. Sowa
A1 Kelsey C. Zorn
A1 Bonny D. Alvarenga
A1 Mars Stone
A1 Philip J. Norris
A1 Wei Gu
A1 Charles Y. Chiu
A1 Joseph L. DeRisi
A1 Michael R. Wilson
YR 2020
UL http://medrxiv.org/content/early/2020/05/13/2020.05.11.20092528.abstract
AB Serologic assays are needed to determine SARS-CoV-2 seroprevalence, but poor specificity can overestimate exposures. Here, we built a pan-human coronavirus proteome-wide programmable phage display assay (VirScan) to profile coronavirus antigens specifically enriched by 20 COVID-19 patient serum IgG. With ReScan, a new diagnostic development workflow which combines the isolation of phage expressing the most immunogenic peptides with paper-based microarrays manufactured via acoustic liquid handling, we identified 9 candidate antigens from a library of 534 SARS-CoV-2 peptides. These arrays could form the basis of a multiplexed COVID-19 serologic assay with enhanced specificity. ReScan has broad applicability for serologic assay development.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported by David Friedberg (C.R.Z. and M.R.W.), NIH grant K08NS096117 (to M.R.W.), the Chan Zuckerberg Biohub (J.L.D. and K.A.Y.), an endowment from the Rachleff family (to M.R.W.), and the Sandler and William K. Bowes, Jr. Foundations (M.R.W., K.C.Z., C.Y.C., S.A.M., and J.L.D.) and the University of California, San Francisco (UCSF) Dean’s Office Medical Student Research Program (G.A.S.).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesVirScan and ReScan data analyzed in the manuscript have been made available at https://github.com/UCSF-Wilson-Lab/sars-cov-2_ReScan_VirScan_complete_analysis https://github.com/UCSF-Wilson-Lab/sars-cov-2_ReScan_VirScan_complete_analysis